Qube Research & Technologies LTD Protalix Bio Therapeutics, Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PLX
# of Institutions
49Shares Held
3.54MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.63 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$739,8620.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$635,3860.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$566,3900.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$459,0000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $84.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...